PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy

被引:16
作者
Bates, AT
Pickles, T
Paltiel, C
机构
[1] Univ British Columbia, British Columbia Canc Agcy, Dept Radiat Oncol, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, British Columbia Canc Agcy, Dept Biostat, Vancouver, BC V5Z 1M9, Canada
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 62卷 / 01期
关键词
prostate cancer; prostate-specific antigen; PSA doubling time; biochemical relapse; radiotherapy;
D O I
10.1016/j.ijrobp.2004.09.048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate whether prostate-specific antigen PSA doubling time (PSADT) is constant in men with biochemical prostate cancer relapse after external beam radiotherapy (EBRT). Methods and Materials: A total of 513 men treated radically with EBRT, with or without androgen ablation (AA), between 1993 and 2000, developed biochemical relapse. The slope of the In (PSA) vs. time graph is calculated for the first two values after PSA nadir (first slope), the last two recorded PSAs (last slope), and all values excluding the first and final PSA (mid slope). Differences in these slopes were compared statistically with subgroup analysis for AA and secondary intervention. Results: For men treated with EBRT and AA first slope was faster than either mid slope (p = 0.031) or last slope (p < 0.001). Men treated with EBRT alone had no change in PSADT over time unless they subsequently received secondary intervention. This group had a more rapid last slope compared with mid slope (p < 0.001). Conclusions: PSA initially rises more rapidly after AA cessation, probably because of testosterone recovery. A subgroup of patients, who received secondary intervention after treatment with radiotherapy alone, showed a change in PSADT, to a faster velocity. This greater than constant exponential PSA growth is presumably the catalyst for secondary intervention. Otherwise, PSADT did not change during prostate cancer biochemical relapse. (c) 2005 Elsevier Inc.
引用
收藏
页码:148 / 153
页数:6
相关论文
共 28 条
  • [11] NATURAL-HISTORY OF CHANGES IN PROSTATE-SPECIFIC ANTIGEN IN EARLY-STAGE PROSTATE-CANCER
    PEARSON, JD
    CARTER, HB
    [J]. JOURNAL OF UROLOGY, 1994, 152 (05) : 1743 - 1748
  • [12] Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma
    Pickles, T
    Agranovich, A
    Berthelet, E
    Duncan, GG
    Keyes, M
    Kwan, W
    McKenzie, MR
    Morris, WJ
    [J]. CANCER, 2002, 94 (02) : 362 - 367
  • [13] Pickles T, 1999, INT J RADIAT ONCOL, V43, P699
  • [14] Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy
    Pinover, WH
    Horwitz, EM
    Hanlon, AL
    Uzzo, RG
    Hanks, GE
    [J]. CANCER, 2003, 97 (04) : 1127 - 1133
  • [15] POLLACK A, 1994, CANCER, V74, P670, DOI 10.1002/1097-0142(19940715)74:2<670::AID-CNCR2820740220>3.0.CO
  • [16] 2-8
  • [17] Natural history of progression after PSA elevation following radical prostatectomy
    Pound, CR
    Partin, AW
    Eisenberger, MA
    Chan, DW
    Pearson, JD
    Walsh, PC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17): : 1591 - 1597
  • [18] A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy
    Pruthi, RS
    Derksen, JE
    Moore, D
    [J]. BJU INTERNATIONAL, 2004, 93 (03) : 275 - 278
  • [19] Roberts SG, 2001, MAYO CLIN PROC, V76, P576
  • [20] Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy
    Sartor, CI
    Strawderman, MH
    Lin, XH
    Kish, KE
    McLaughlin, PW
    Sandler, HM
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (05): : 941 - 947